@prefix : <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix opv: <http://inab.certh.gr/OpenPVSignal> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix openpvsignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl> .
@base <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl> .

<http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl> rdf:type owl:Ontology ;
                                                                              owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ;
                                                                              rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/272966/"^^xsd:anyURI ;
                                                                              rdfs:label "Vemurafenib and cardiac failure"^^rdfs:Literal ;
                                                                              owl:versionInfo "draft-v0.95-20210226"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> rdf:type owl:ObjectProperty .


###  http://purl.org/mp/publishedBy
mp:publishedBy rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Data properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> rdfs:subPropertyOf <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> .


###  http://www.w3.org/2006/time#days
<http://www.w3.org/2006/time#days> rdf:type owl:DatatypeProperty .


#################################################################
#    Classes
#################################################################

###  http://www.w3.org/2006/time#DurationDescription
<http://www.w3.org/2006/time#DurationDescription> rdf:type owl:Class .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Acenocoumarol
:Acenocoumarol rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AA07" ;
               rdfs:label "acenocoumarol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Acetylsalicylicacid
:Acetylsalicylicacid rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A01AD05" ;
                     rdfs:label "acetylsalicylic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Aciclovir
:Aciclovir rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J05AB01" ;
           rdfs:label "aciclovir" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Alopecia
:Alopecia rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L65.9" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10001760 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Alopecia" ;
          rdfs:label "alopecia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Alprazolam
:Alprazolam rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA12" ;
            rdfs:label "alprazolam" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Amitriptyline
:Amitriptyline rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AA09" ;
               rdfs:label "amitriptyline" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Anticancer_drugs
:Anticancer_drugs rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01" ;
                  rdfs:label "Anticancer drugs" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Antidepressants
:Antidepressants rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06A" ;
                 rdfs:label "Antidepressants" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Antidiabetic_drugs
:Antidiabetic_drugs rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10" ;
                    rdfs:label "Antidiabetic drugs" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Antifungal_drugs
:Antifungal_drugs rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D01" ;
                  rdfs:label "Antifungal drugs" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Antimigraine_drugs
:Antimigraine_drugs rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02C" ;
                    rdfs:label "Antimigraine drugs" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Arthralgia
:Arthralgia rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> " M26.62" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10003239 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Arthralgia" ;
            rdfs:label "arthralgia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#BRAFV600PositiveMetastaticOrUnresectableMelanoma
:BRAFV600PositiveMetastaticOrUnresectableMelanoma rdf:type owl:NamedIndividual ,
                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10053571 ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Melanoma" ;
                                                  rdfs:label "BRAF V600 positive metastatic or unresectable melanoma" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Bisoprolol
:Bisoprolol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AB07 " ;
            rdfs:label "bisoprolol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Bromazepam
:Bromazepam rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA08" ;
            rdfs:label "bromazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#CNSVentriculitis
:CNSVentriculitis rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G04.90" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10009719 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "CNS ventriculitis" ;
                  rdfs:label "CNS ventriculitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#CardiacFailure
:CardiacFailure rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I50" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10007554 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cardiac failure " ;
                rdfs:label "cardiac failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#CardiacFailureAcute
:CardiacFailureAcute rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I50.9" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10007556 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cardiac failure acute" ;
                     rdfs:label "cardiac failure acute" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#CardiacFailureCongestive
:CardiacFailureCongestive rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I50.9" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10007559 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cardiac failure congestive" ;
                          rdfs:label "cardiac failure congestive" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Cardiac_failure_pathophysiology
:Cardiac_failure_pathophysiology rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                                 mp:references :Ref.2 ,
                                               :Ref.3 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Cardiac failure is a condition in which the heart is unable to pump an adequate amount of blood to meet the metabolic and physiological needs of the body. Cases are often classified using the four stages according to the New York Heart Association.2 Basic requirements for use of the term, according to CIOMS, include any three of the following: 
• dependent oedema, 
• raised jugular venous pressure or hepatomegaly in the absence of liver disease, 
• signs of pulmonary congestion or effusion, 
• rapid heart-rate (>100 beats/min) or gallop rhythm, 
• enlarged heart, 
• dyspnoea in the absence of pulmonary disease, or 
• ejection fraction less than 35 per cent.2

A large number of drugs have been implicated as a cause of cardiac failure. These include anticancer agents such as anthracyclines, mitoxantrone, cyclophosphamide, fluorouracil, capecitabine and trastuzumab; immunomodulating drugs such as interferon-α-2, interleukin-2, infliximab and etanercept; antidiabetic drugs such as rosiglitazone, pioglitazone and troglitazone; antimigraine drugs such as ergotamine and methysergide; appetite suppressants such as fenfluramine, dexfenfluramine and phentermine; tricyclic antidepressants; antipsychotic drugs such as clozapine; antiparkinsonian drugs such as pergolide and cabergoline; NSAIDs, glucocorticoids; and antifungal drugs such as itraconazole and amphotericin B.3""" ;
                                 rdfs:label "Cardiac failure pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Clonazepam
:Clonazepam rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AE01" ;
            rdfs:label "clonazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Cloperastine
:Cloperastine rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R05DB21" ;
              rdfs:label "cloperastine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Clopidogrel
:Clopidogrel rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AC04" ;
             rdfs:label "clopidogrel" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#CutaneousSquamousCellCarcinoma
:CutaneousSquamousCellCarcinoma rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C44.92" ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10041834 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Squamous cell carcinoma of skin" ;
                                rdfs:label "squamous cell carcinoma" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Dechallenge_information_favoring_vemurafenib
:Dechallenge_information_favoring_vemurafenib rdf:type owl:NamedIndividual ,
                                                       <http://purl.obolibrary.org/obo/OAE_0001197> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ,
                                                                                                             :cobinetinib ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In the five reports where the patient had not recovered, both drugs were withdrawn in two cases, both drugs were continued then stopped in one case, vemurafenib was continued and cobimetinib withdrawn in one case and vemurafenib continued and then stopped and cobimetinib withdrawn in the remaining case. This information appears to slightly favour vemurafenib as the most likely drug. In the remaining six cases in which there was" ;
                                              rdfs:label "Dechallenge information favoring vemurafenib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#DermatologicalReactions
:DermatologicalReactions rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L27.0" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10040914 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Skin reaction" ;
                         rdfs:label "dermatological reactions" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Digoxin
:Digoxin rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01AA05" ;
         rdfs:label "digoxin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Doxazosin
:Doxazosin rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C02CA04" ;
           rdfs:label "doxazosin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Dr._Ian_Boyd
:Dr._Ian_Boyd rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "Australia" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Ian" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Boyd" ;
              rdfs:label "Dr. Ian Boyd" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#EU_SmPC_and_US_FDA_label_for_vemurafenib
:EU_SmPC_and_US_FDA_label_for_vemurafenib rdf:type owl:NamedIndividual ,
                                                   <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CutaneousSquamousCellCarcinoma ,
                                                                                                                   :QTProlongation ,
                                                                                                                   :atrialFibrillation ,
                                                                                                                   :cardiacDisorder ,
                                                                                                                   :decreasedAppetite ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                                          mp:references :Ref.1 ,
                                                        :Ref.4 ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Currently, the only cardiac events mentioned in the ADR section of the product labels are QT prolongation (EU SmPC) and atrial fibrillation (US FDA label).1,4 The EU SmPC does mention that “older patients (≥ 65 years) may be more likely to experience adverse reactions, including cuSCC, decreased appetite, and cardiac disorders.”" ;
                                          rdfs:label "EU SmPC and US FDA label for vemurafenib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Enoxaparin
:Enoxaparin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AB05" ;
            rdfs:label "enoxaparin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Erythromycin
:Erythromycin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D10AF02" ;
              rdfs:label "erythromycin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Esomeprazole
:Esomeprazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC05" ;
              rdfs:label "esomeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Everolimus
:Everolimus rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01XE10" ;
            rdfs:label "everolimus" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Fatigue
:Fatigue rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R53.83" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10016256 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Fatigue" ;
         rdfs:label "fatigue" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Fenofibrate
:Fenofibrate rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AB05" ;
             rdfs:label "fenofibrate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Furosemide
:Furosemide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA01" ;
            rdfs:label "furosemide" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Hypersensitivity
:Hypersensitivity rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "T78.40 " ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013700 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Drug hypersensitivity" ;
                  rdfs:label "Hypersensitivity" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#IC025_of_Vemurafenib_in_Vigibas
:IC025_of_Vemurafenib_in_Vigibas rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_information_component> <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#IC_(Information_Component)_of_Vemurafenib_in_Vigibas> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "10/09/2016" ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> -0.17 ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 61 ;
                                 rdfs:label "IC025 of Vemurafenib in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ifosfamide
:Ifosfamide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01AA06" ;
            rdfs:label "Ifosfamide" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Joint_pain
:Joint_pain rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M25.50" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10023222 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Joint pain" ;
            rdfs:label "joint pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#LeftVentricularDysfunction
:LeftVentricularDysfunction rdf:type owl:NamedIndividual ,
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I50.1" ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10049694 ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Left ventricular dysfunction" ;
                            rdfs:label "left ventricular dysfunction" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Levofloxacin
:Levofloxacin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01MA12" ;
              rdfs:label "levofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Lisinopril
:Lisinopril rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09AA03" ;
            rdfs:label "lisinopril" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Literature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                          mp:references :Ref.1 ,
                                        :Ref.4 ,
                                        :Ref.5 ,
                                        :Ref.6 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The product literature does not refer to cardiac failure. Currently, the only cardiac events mentioned in the ADR section of the product labels are QT prolongation (EU SmPC) and atrial fibrillation (US FDA label).1,4 The EU SmPC does mention that “older patients (≥ 65 years) may be more likely to experience adverse reactions, including cuSCC, decreased appetite, and cardiac disorders.”1 There are no reports in the literature of cardiac failure in association with vemurafenib. There is a report of QT prolongation in association with treatment with vemurafenib in end stage renal disease although the authors assessed that the probability of this being an adverse drug reaction was low.5 The product information for another BRAF enzyme inhibitor, dabrafenib, has a warning that dabrafenib in combination with trametinib has been reported to decrease left ventricular ejection fraction (LVEF).6 It also lists ejection fraction decreased as a common adverse reaction but this adverse reaction arises from combination with trametinib and not dabrafenib alone." ;
                          rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Losartan
:Losartan rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09CA01" ;
          rdfs:label "losartan" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Mechanism_of_cobimetinib
:Mechanism_of_cobimetinib rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Cobimetinib is also a kinase inhibitor but cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway." ;
                          rdfs:label "Mechanism of cobimetinib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Mechanism_of_vemurafenib
:Mechanism_of_vemurafenib rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                          mp:references :Ref.1 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase (a member of the Raf kinase family of growth signal transduction protein kinases). Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation.1 Before taking vemurafenib, patients must have BRAF V600 mutation-positive tumour status confirmed by a validated test. It is one of the medications widely known as tyrosine kinase inhibitors (TKIs) but should be referred to as protein kinase inhibitors because although the earliest drugs in this class were TKIs, they can now be further categorized based upon the amino acid that they phosphorylate: serine, threonine or tyrosine." ;
                          rdfs:label "Mechanism of vemurafenib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Meropenem
:Meropenem rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01DH02" ;
           rdfs:label "meropenem" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#MetastaticThyroidCancer
:MetastaticThyroidCancer rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C73" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10066474 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Thyroid cancer" ;
                         rdfs:label "Metastatic thyroid cancer" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Metformin
:Metformin rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BA02" ;
           rdfs:label "metformin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Metoprolol
:Metoprolol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AB02" ;
            rdfs:label "metoprolol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Milrinone
:Milrinone rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01CE02 " ;
           rdfs:label "milrinone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Muscle_pain
:Muscle_pain rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M79.1" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028322 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Muscle pain" ;
             rdfs:label "muscle pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Nausea
:Nausea rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R11.0" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028817 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Nausea and vomiting symptoms" ;
        rdfs:label "nausea" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Neoplasm
:Neoplasm rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C80. 1" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028997 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Neoplasm malignant" ;
          rdfs:label "Neoplasm" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Omeprazole
:Omeprazole rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC01" ;
            rdfs:label "omeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#OverallReportsInVigibase
:OverallReportsInVigibase rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 59 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 30 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 24 ;
                          rdfs:label "Overall Reports In Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Overall_Reports_with_age_information
:Overall_Reports_with_age_information rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 44 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 88 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_median_age> 67 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 9 ;
                                      rdfs:label "Overall Reports with age information" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#PV_Signal
:PV_Signal rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Signal> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> :Cardiac_failure_pathophysiology ,
                                                                                       :Reports_in_Vigibase ,
                                                                                       :conclusion ,
                                                                                       :introduction ,
                                                                                       :summary ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_individual_case_report> :Report1 ,
                                                                                                  :Report10 ,
                                                                                                  :Report11 ,
                                                                                                  :Report12 ,
                                                                                                  :Report13 ,
                                                                                                  :Report14 ,
                                                                                                  :Report15 ,
                                                                                                  :Report16 ,
                                                                                                  :Report17 ,
                                                                                                  :Report18 ,
                                                                                                  :Report19 ,
                                                                                                  :Report2 ,
                                                                                                  :Report20 ,
                                                                                                  :Report21 ,
                                                                                                  :Report22 ,
                                                                                                  :Report23 ,
                                                                                                  :Report24 ,
                                                                                                  :Report25 ,
                                                                                                  :Report26 ,
                                                                                                  :Report27 ,
                                                                                                  :Report28 ,
                                                                                                  :Report29 ,
                                                                                                  :Report3 ,
                                                                                                  :Report30 ,
                                                                                                  :Report31 ,
                                                                                                  :Report32 ,
                                                                                                  :Report33 ,
                                                                                                  :Report34 ,
                                                                                                  :Report35 ,
                                                                                                  :Report36 ,
                                                                                                  :Report37 ,
                                                                                                  :Report38 ,
                                                                                                  :Report39 ,
                                                                                                  :Report4 ,
                                                                                                  :Report40 ,
                                                                                                  :Report41 ,
                                                                                                  :Report42 ,
                                                                                                  :Report43 ,
                                                                                                  :Report44 ,
                                                                                                  :Report45 ,
                                                                                                  :Report46 ,
                                                                                                  :Report47 ,
                                                                                                  :Report48 ,
                                                                                                  :Report49 ,
                                                                                                  :Report5 ,
                                                                                                  :Report50 ,
                                                                                                  :Report51 ,
                                                                                                  :Report52 ,
                                                                                                  :Report53 ,
                                                                                                  :Report54 ,
                                                                                                  :Report55 ,
                                                                                                  :Report56 ,
                                                                                                  :Report57 ,
                                                                                                  :Report58 ,
                                                                                                  :Report59 ,
                                                                                                  :Report6 ,
                                                                                                  :Report60 ,
                                                                                                  :Report61 ,
                                                                                                  :Report7 ,
                                                                                                  :Report8 ,
                                                                                                  :Report9 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_statistical_entity> :IC025_of_Vemurafenib_in_Vigibas ,
                                                                                              :OverallReportsInVigibase ,
                                                                                              :Overall_Reports_with_age_information ,
                                                                                              :ReportsHavingFatalOutcome ,
                                                                                              :ReportsHavingMetastaticNeoplasmAsIndication ,
                                                                                              :ReportsHavingMetastaticThyroidCancerAsIndication ,
                                                                                              :ReportsHavingVemurafenibAsPrimarySuspectDrug ,
                                                                                              :ReportsThatDidNotRecover ,
                                                                                              :Reports_from_Australia ,
                                                                                              :Reports_from_Canada ,
                                                                                              :Reports_from_Czech_Republic ,
                                                                                              :Reports_from_France ,
                                                                                              :Reports_from_Germany ,
                                                                                              :Reports_from_Italy ,
                                                                                              :Reports_from_Japan ,
                                                                                              :Reports_from_Spain ,
                                                                                              :Reports_from_United_Kingdom ,
                                                                                              :Reports_from_United_States ,
                                                                                              :Reports_from_the_Netherlands ,
                                                                                              :Reports_having_cobimetinib_as_co_suspected_drug ,
                                                                                              :Reports_having_everolimus_as_co_suspected_drug ,
                                                                                              :Reports_having_ifosfamide_as_co_suspected_drug ,
                                                                                              :Reports_having_loxoprofen_as_co_suspected_drug ,
                                                                                              :Reports_having_methotrexate_as_co_suspected_drug ,
                                                                                              :Reports_with_atrial_fibrillation ,
                                                                                              :Reports_with_dyspnoea ,
                                                                                              :Reports_with_joint_and_muscle_pain ,
                                                                                              :Reports_with_pleural_effusion ,
                                                                                              :Reports_with_pneumonia ,
                                                                                              :Reports_with_renal_impairement_and_failure ,
                                                                                              :Reports_with_skin_reactions ,
                                                                                              :age_of_patients_that_are_likely_to_develop_cardiac_failure ,
                                                                                              <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#IC_(Information_Component)_of_Vemurafenib_in_Vigibas> ,
                                                                                              <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ReportsHavingmetastatic/malignantMelanomaAsIndication> ,
                                                                                              <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_fatigue/_malaise> ,
                                                                                              <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_myocarditis/_pericarditis/_cardiomyopathy> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
           mp:supportedByData :Dechallenge_information_favoring_vemurafenib ,
                              :EU_SmPC_and_US_FDA_label_for_vemurafenib ,
                              :Product_information_for_cobimetinib ,
                              :Product_information_for_everolimus ,
                              :Product_information_for_vemurafenib ,
                              :Warning_information_for_dabrafenib ,
                              :δδ ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#initially_identified_on> "01/07/2018" ;
           rdfs:label "PV Signal" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Paracetamol
:Paracetamol rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02BE01 " ;
             rdfs:label "paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient10
:Patient10 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 67 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient11
:Patient11 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 41 ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient12
:Patient12 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 76 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient13
:Patient13 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 74 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient14
:Patient14 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 61 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient15
:Patient15 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 40 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 15" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient16
:Patient16 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 67 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 16" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient17
:Patient17 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 77 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient18
:Patient18 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 32 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient19
:Patient19 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 74 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient20
:Patient20 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 74 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient21
:Patient21 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 75 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 21" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient22
:Patient22 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 65 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 22" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient23
:Patient23 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 45 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 23" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient24
:Patient24 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 24" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient25
:Patient25 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 62 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 25" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient26
:Patient26 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 39 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 26" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient27
:Patient27 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 59 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 27" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient28
:Patient28 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 44 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 28" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient29
:Patient29 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 75 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 29" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient30
:Patient30 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 71 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 30" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient31
:Patient31 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 75 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 31" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient32
:Patient32 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 60 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 32" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient33
:Patient33 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 72 ;
           rdfs:label "Patient 33" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient34
:Patient34 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 84 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 34" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient35
:Patient35 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 75 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 35" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient36
:Patient36 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 74 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 36" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient37
:Patient37 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 37" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient38
:Patient38 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 66 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 38" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient39
:Patient39 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           rdfs:label "Patient 39" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 56 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient40
:Patient40 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 75 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 40" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient41
:Patient41 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 9 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 41" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient42
:Patient42 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 88 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 42" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient43
:Patient43 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 66 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 43" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient44
:Patient44 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 44" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient45
:Patient45 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 73 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 45" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient46
:Patient46 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 66 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 46" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient47
:Patient47 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 61 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 47" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient48
:Patient48 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 68 ;
           rdfs:label "Patient 48" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient49
:Patient49 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 49" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 47 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient50
:Patient50 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 50" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient51
:Patient51 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 51" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient52
:Patient52 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 52" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient53
:Patient53 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 53" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient54
:Patient54 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 50 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 54" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient55
:Patient55 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 55" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient56
:Patient56 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 74 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 56" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient57
:Patient57 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 77 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 57" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient58
:Patient58 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 58" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient59
:Patient59 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 59" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 76 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient60
:Patient60 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 87 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 60" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient61
:Patient61 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 66 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 61" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient7
:Patient7 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 66 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient8
:Patient8 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Patient9
:Patient9 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 61 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#PhotosensitivityReaction
:PhotosensitivityReaction rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L56.8" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10034972 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Photosensitivity reaction" ;
                          rdfs:label "photosensitivity reaction" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Potassium
:Potassium rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B05XA01" ;
           rdfs:label "potassium" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Pregabalin
:Pregabalin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AX16" ;
            rdfs:label "pregabalin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Product_information_for_cobimetinib
:Product_information_for_cobimetinib rdf:type owl:NamedIndividual ,
                                              <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :LeftVentricularDysfunction ,
                                                                                                              :QTProlongation ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :cobinetinib ;
                                     mp:references :Ref.7 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In the product information for cobimetinib, there is a warning concerning both the possibility of QT prolongation and advice that a decrease in LVEF from baseline has been reported in patients receiving cobimetinib. Median time to initial onset of events was four months (1-13 months).7" ;
                                     rdfs:label "Product information for cobimetinib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Product_information_for_everolimus
:Product_information_for_everolimus rdf:type owl:NamedIndividual ,
                                             <http://purl.obolibrary.org/obo/OAE_0001182> ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Everolimus ;
                                    mp:references :Ref.8 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "the product information lists congestive cardiac failure as an uncommon adverse effect for everolimus.8" ;
                                    rdfs:label "Product information for everolimus" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Product_information_for_vemurafenib
:Product_information_for_vemurafenib rdf:type owl:NamedIndividual ,
                                              <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_part_of> :introduction ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CutaneousSquamousCellCarcinoma ,
                                                                                                              :DermatologicalReactions ,
                                                                                                              :Hypersensitivity ,
                                                                                                              :PhotosensitivityReaction ,
                                                                                                              :QTProlongation ,
                                                                                                              :liverLaboratoryAbnormalities ,
                                                                                                              :melanoma ,
                                                                                                              :ophthalmologicReactions ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                                     mp:references :Ref.1 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "There are warnings in the product information concerning the possible occurrence of severe hypersensitivity and dermatological reactions, QT prolongation, serious ophthalmologic reactions, non-cuSCC, new primary melanomas, liver laboratory abnormalities and mild to severe photosensitivity.1" ;
                                     rdfs:label "Product information for vemurafenib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Pruritus
:Pruritus rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L29.9" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037087 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pruritus" ;
          rdfs:label "pruritus" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#QTProlongation
:QTProlongation rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I45.81" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037703 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "QT interval prolonged" ;
                rdfs:label "QT prolongation" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Rabeprazole
:Rabeprazole rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC04" ;
             rdfs:label "rabeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Rash
:Rash rdf:type owl:NamedIndividual ,
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R21" ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037844 ;
      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Rash" ;
      rdfs:label "rash" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "European Medicines Agency. Summary ofProduct Characteristics for vemurafenib(Zelboraf®). Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002409/WC500124317.pdf. Accessed:14 September 2017." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The Council for International Organizations ofMedical Sciences (CIOMS). Reporting adverse drug reactions: definitions of terms and criteriafor their use. CIOMS, Geneva, 1999. Availablefrom: https://cioms.ch/wpcontent/uploads/2017/01/reporting_adverse_drug. pdf. Accessed: 14 September 2017." ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Slordal L, Spigset O. Heart failure inducedby noncardiac drugs, Drug Saf. 2006;29:567-86." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "US Food and Drug Administration. Zelboraf(vemurafenib) Label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202429s009lbl.pdf. Accessed: 25September 2017." ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Iddawela M, Crook S, George L, Lakkaraju A,Nanayakkara N, Hunt R, Adam WR. Safety andefficacy of vemurafenib in end stage renalfailure. BMC Cancer. 2013;13:581." ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "European Medicines Agency. Summary ofProduct Characteristics for dabrafenib(Tafinlar®). Available from:http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/002604/WC500149671.pdf. Accessed: 4 October 2017." ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "European Medicines Agency. Summary ofProduct Characteristics for cobimetinib(Cotellic®). Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003960/WC500198563.pdf.Accessed: September 2017." ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Electronic Medicines Compendium.Summary of Product Characteristics foreverolimus (Afinitor®). Available from:http://www.medicines.org.uk/emc/medicine/22281. Accessed: September 2017." ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kwon HJ, Cot TR, Cuffe MS, Kramer JM,Braun MM. Case reports of heart failureafter therapy with a tumor necrosis factorantagonist. Ann Intern Med.2003;138:807-11." ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                  :pneumonia ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report10
:Report10 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Paracetamol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report11
:Report11 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Bromazepam ,
                                                                                     :Esomeprazole ,
                                                                                     :Paracetamol ,
                                                                                     :Potassium ,
                                                                                     :fentanyl ,
                                                                                     :levetiracetam ,
                                                                                     :mirtazapine ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report12
:Report12 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acenocoumarol ,
                                                                                     :Digoxin ,
                                                                                     :Metoprolol ,
                                                                                     :bumetanide ,
                                                                                     :nadroparin ,
                                                                                     :spironolactone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient12 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report13
:Report13 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :interstitialLungDisease ,
                                                                                   :myocarditis ,
                                                                                   :pleuralEffusion ,
                                                                                   :pulmonaryOedema ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetylsalicylicacid ,
                                                                                     :Rabeprazole ,
                                                                                     :insulinAspart ,
                                                                                     :insulinGlargine ,
                                                                                     :insulinHuman ,
                                                                                     :teneligliptin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient13 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report14
:Report14 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :acuteKidneyInjury ,
                                                                                   :acuteRespiratoryDistressSyndrome ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Meropenem ,
                                                                                     :methylprednisolone ,
                                                                                     :prednisolone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient14 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report15
:Report15 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Cloperastine ,
                                                                                     :lorazepam ,
                                                                                     :loxoprofen ,
                                                                                     :metronidazole ,
                                                                                     :potassiumAspartate ,
                                                                                     :rilmazafone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient15 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ifosfamide ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 15" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report16
:Report16 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient16 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 16" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report17
:Report17 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetylsalicylicacid ,
                                                                                     :Fenofibrate ,
                                                                                     :betahistine ,
                                                                                     :pantoprazole ,
                                                                                     :prednisolone ,
                                                                                     :tamsulosin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient17 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report18
:Report18 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :haemolyticUraemicSyndromeAcute ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :tramadol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient18 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report19
:Report19 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :atrialFibrillation ,
                                                                                   :renalFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Doxazosin ,
                                                                                     :Enoxaparin ,
                                                                                     :Furosemide ,
                                                                                     :Levofloxacin ,
                                                                                     :Metoprolol ,
                                                                                     :Paracetamol ,
                                                                                     :cetirizine ,
                                                                                     :dutasteride ,
                                                                                     :hydrocodoneParacetamol ,
                                                                                     :ibuprofen ,
                                                                                     :levothyroxine ,
                                                                                     :metolazone ,
                                                                                     :naproxen ,
                                                                                     :serenoaRepens ,
                                                                                     :tamsulosin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient19 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report20
:Report20 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :atrialFibrillation ,
                                                                                   :generalisedOedema ,
                                                                                   :pyrexia ,
                                                                                   :renalFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Doxazosin ,
                                                                                     :Enoxaparin ,
                                                                                     :Furosemide ,
                                                                                     :Levofloxacin ,
                                                                                     :Metoprolol ,
                                                                                     :Paracetamol ,
                                                                                     :cetirizine ,
                                                                                     :dutasteride ,
                                                                                     :hydrocodoneParacetamol ,
                                                                                     :ibuprofen ,
                                                                                     :levothyroxine ,
                                                                                     :metolazone ,
                                                                                     :naproxen ,
                                                                                     :serenoaRepens ,
                                                                                     :tamsulosin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient20 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report21
:Report21 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :respiratoryDistress ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Tinzaparin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient21 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
          rdfs:label "Report 21" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report22
:Report22 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :LeftVentricularDysfunction ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient22 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 22" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report23
:Report23 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient23 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 23" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report24
:Report24 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :bacterialPericarditis ,
                                                                                   :pleuropericarditis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Sertraline ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient24 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with sequelae" ;
          rdfs:label "Report 24" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report25
:Report25 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient25 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 25" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report26
:Report26 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :toxicEpidermalNecrolysis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Losartan ,
                                                                                     :Metformin ,
                                                                                     :risperidone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient26 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :loxoprofen ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 26" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report27
:Report27 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Fatigue ,
                                                                                   :Nausea ,
                                                                                   :abdominalDiscomfort ,
                                                                                   :asthenia ,
                                                                                   :backpain ,
                                                                                   :diarrhoea ,
                                                                                   :ejectionFractionDecreased ,
                                                                                   :electrolyteImbalance ,
                                                                                   :generalPhysicalHealthDeterioration ,
                                                                                   :hepaticEnzymeIncreased ,
                                                                                   :hyperkeratosis ,
                                                                                   :metastasesToLiver ,
                                                                                   :musculoskeletalChestPain ,
                                                                                   :vomiting ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetylsalicylicacid ,
                                                                                     :Simvastatin ,
                                                                                     :prasugrel ,
                                                                                     :ramipril ,
                                                                                     :torasemide ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient27 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 27" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report28
:Report28 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ,
                                                                                   :erythemaNodosum ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient28 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 28" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report29
:Report29 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :metastaticMalignantMelanoma ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient29 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 29" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report30
:Report30 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Levofloxacin ,
                                                                                     :Lisinopril ,
                                                                                     :levothyroxine ,
                                                                                     :macrogol ,
                                                                                     :oxycodone ,
                                                                                     :prochlorperazine ,
                                                                                     :thiocticAcid ,
                                                                                     :tocopherol ,
                                                                                     :vitaminb12 ,
                                                                                     :warfarin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient30 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :placebo ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 30" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report31
:Report31 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient31 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 31" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report32
:Report32 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :LeftVentricularDysfunction ,
                                                                                   :atrialFibrillation ,
                                                                                   :cardiomyopathy ,
                                                                                   :pericardialEffusion ,
                                                                                   :pleuralEffusion ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetylsalicylicacid ,
                                                                                     :Omeprazole ,
                                                                                     :Potassium ,
                                                                                     :Sertraline ,
                                                                                     :amoxicillinClavulanicAcid ,
                                                                                     :atorvastatin ,
                                                                                     :benzonatate ,
                                                                                     :codeineGuaifenesin ,
                                                                                     :dutasteride ,
                                                                                     :fentanyl ,
                                                                                     :hydrocodoneParacetamol ,
                                                                                     :loratadine ,
                                                                                     :morphine ,
                                                                                     :nicotine ,
                                                                                     :oxycodone ,
                                                                                     :prochlorperazine ,
                                                                                     :solifenacin ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient32 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :placebo ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 32" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report33
:Report33 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient33 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 33" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report34
:Report34 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Arthralgia ,
                                                                                   :CardiacFailure ,
                                                                                   :abdominalDistension ,
                                                                                   :bloodBilirubinIncreased ,
                                                                                   :dyspnoea ,
                                                                                   :polymeraseChainReaction ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acenocoumarol ,
                                                                                     :Alprazolam ,
                                                                                     :Clopidogrel ,
                                                                                     :Furosemide ,
                                                                                     :Levofloxacin ,
                                                                                     :Paracetamol ,
                                                                                     :Simvastatin ,
                                                                                     :Zolpidem ,
                                                                                     :amlodipine ,
                                                                                     :domperidone ,
                                                                                     :glyceryltrinitrate ,
                                                                                     :levosulpiride ,
                                                                                     :oxygen ,
                                                                                     :ramipril ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient34 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 34" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report35
:Report35 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Bisoprolol ,
                                                                                     :Erythromycin ,
                                                                                     :Furosemide ,
                                                                                     :Metformin ,
                                                                                     :Simvastatin ,
                                                                                     :insulinLispro ,
                                                                                     :pantoprazole ,
                                                                                     :phenprocoumon ,
                                                                                     :ramipril ,
                                                                                     :spironolactone ,
                                                                                     :tolterodine ,
                                                                                     :torasemide ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient35 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 35" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report36
:Report36 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :electrocardiogramQTProlonged ,
                                                                                   :visualImpairment ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient36 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 36" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report37
:Report37 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :Fatigue ,
                                                                                   :confusionalState ,
                                                                                   :dehydration ,
                                                                                   :heartRateIncreased ,
                                                                                   :hypotension ,
                                                                                   :pneumonia ,
                                                                                   :renalFailure ,
                                                                                   :urinaryTractInfection ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient37 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 37" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report38
:Report38 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :Rash ,
                                                                                   :musculoskeletalPain ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient38 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 38" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report39
:Report39 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :chronicObstructivePulmonaryDisease ,
                                                                                   :hypertension ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient39 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 39" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Digoxin ,
                                                                                    :carvedilol ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report40
:Report40 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :anginaPectoris ,
                                                                                   :electrocardiogramQTProlonged ,
                                                                                   :myocardialInfarction ,
                                                                                   :pneumonia ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetylsalicylicacid ,
                                                                                     :Clopidogrel ,
                                                                                     :Furosemide ,
                                                                                     :Lisinopril ,
                                                                                     :Sertraline ,
                                                                                     :Simvastatin ,
                                                                                     :Zolpidem ,
                                                                                     :benzonatate ,
                                                                                     :carvedilol ,
                                                                                     :glyceryltrinitrate ,
                                                                                     :hydroxyzine ,
                                                                                     :isosorbide_mononitrate ,
                                                                                     :levothyroxine ,
                                                                                     :lidocaine ,
                                                                                     :lorazepam ,
                                                                                     :mesalazine ,
                                                                                     :ondansetron ,
                                                                                     :oxycodone ,
                                                                                     :salbutamol ,
                                                                                     :tolterodine ,
                                                                                     :tramadol ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient40 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with sequelae" ;
          rdfs:label "Report 40" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report41
:Report41 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CNSVentriculitis ,
                                                                                   :CardiacFailure ,
                                                                                   :cardiomyopathy ,
                                                                                   :neoplasmProgression ,
                                                                                   :seizure ,
                                                                                   :shuntInfection ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :carboplatin ,
                                                                                     :celecoxib ,
                                                                                     :gabapentin ,
                                                                                     :lamotrigine ,
                                                                                     :levetiracetam ,
                                                                                     :levothyroxine ,
                                                                                     :morphine ,
                                                                                     :temozolomide ,
                                                                                     :vincristine ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient41 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
          rdfs:label "Report 41" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report42
:Report42 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient42 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
          rdfs:label "Report 42" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report43
:Report43 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :acuteKidneyInjury ,
                                                                                   :pneumonia ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetylsalicylicacid ,
                                                                                     :Furosemide ,
                                                                                     :Lisinopril ,
                                                                                     :atorvastatin ,
                                                                                     :carvedilol ,
                                                                                     :fluticasone ,
                                                                                     :pantoprazole ,
                                                                                     :paroxetine ,
                                                                                     :salbutamol ,
                                                                                     :spironolactone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient43 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with sequelae" ;
          rdfs:label "Report 43" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report44
:Report44 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :acuteKidneyInjury ,
                                                                                   :pneumonia ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Milrinone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient44 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 44" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report45
:Report45 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :acuteKidneyInjury ,
                                                                                   :pulmonaryOedema ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient45 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 45" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report46
:Report46 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :acuteCoronarySyndrome ,
                                                                                   :diffuseAlveolarDamage ,
                                                                                   :dyspnoea ,
                                                                                   :myocardialIschaemia ,
                                                                                   :opportunisticInfection ,
                                                                                   :pulmonaryAlveolarHaemorrhage ,
                                                                                   :pulmonaryOedema ,
                                                                                   :respiratoryFailure ,
                                                                                   :toxicityToVariousAgents ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :ciclosporin ,
                                                                                     :methylprednisolone ,
                                                                                     :mycophenolicAcid ,
                                                                                     :tacrolimus ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient46 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Everolimus ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
          rdfs:label "Report 46" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report47
:Report47 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureAcute ,
                                                                                   :acuteKidneyInjury ,
                                                                                   :bloodCreatinineIncreased ,
                                                                                   :bloodUreaIncreased ,
                                                                                   :dyspnoea ,
                                                                                   :oedema ,
                                                                                   :pleuralEffusion ,
                                                                                   :renalImpairment ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :dexamethasone ,
                                                                                     :spironolactone ,
                                                                                     :zopiclone ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#codeine/paracetamol> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient47 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 47" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report48
:Report48 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :LeftVentricularDysfunction ,
                                                                                   :asthenia ,
                                                                                   :cardiomyopathy ,
                                                                                   :decreasedAppetite ,
                                                                                   :dehydration ,
                                                                                   :dyspnoea ,
                                                                                   :lowerRespiratoryTractInfection ,
                                                                                   :mucosalInflammation ,
                                                                                   :orthopnoea ,
                                                                                   :pneumonia ,
                                                                                   :poorQualitySleep ,
                                                                                   :productiveCough ,
                                                                                   :renalFunctionTestAbnormal ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient48 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 48" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report49
:Report49 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :cardiacDisorder ,
                                                                                   :ejectionFractionDecreased ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient49 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 49" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                  :ejectionFractionDecreased ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report50
:Report50 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :acuteKidneyInjury ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient50 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 50" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report51
:Report51 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Arthralgia ,
                                                                                   :CardiacFailureCongestive ,
                                                                                   :Fatigue ,
                                                                                   :Nausea ,
                                                                                   :Pruritus ,
                                                                                   :Rash ,
                                                                                   :blister ,
                                                                                   :breastPain ,
                                                                                   :breastSwelling ,
                                                                                   :chills ,
                                                                                   :diarrhoea ,
                                                                                   :eyePruritus ,
                                                                                   :headache ,
                                                                                   :jointSwelling ,
                                                                                   :nippleSwelling ,
                                                                                   :oropharyngealPain ,
                                                                                   :sunburn ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient51 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 51" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report52
:Report52 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureAcute ,
                                                                                   :bronchitis ,
                                                                                   :pancytopenia ,
                                                                                   :pneumonia ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Amitriptyline ,
                                                                                     :Clonazepam ,
                                                                                     :Esomeprazole ,
                                                                                     :Furosemide ,
                                                                                     :Losartan ,
                                                                                     :Potassium ,
                                                                                     :Sodium ,
                                                                                     :amlodipine ,
                                                                                     :ascorbicAcid ,
                                                                                     :calcium ,
                                                                                     :duloxetine ,
                                                                                     :fishOil ,
                                                                                     :hydrocodoneParacetamol ,
                                                                                     :leflunomide ,
                                                                                     :lorazepam ,
                                                                                     :topirimate ,
                                                                                     :verapamil ,
                                                                                     :vitamins ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient52 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :methotrexate ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 52" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report53
:Report53 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :dehydration ,
                                                                                   :liverFunctionTestAbnormal ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :gabapentin ,
                                                                                     :morphine ,
                                                                                     :ondansetron ,
                                                                                     :oxycodone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient53 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
          rdfs:label "Report 53" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report54
:Report54 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :death ,
                                                                                   :fluidRetention ,
                                                                                   :myocardialInfarction ,
                                                                                   :pneumonitis ,
                                                                                   :pulmonaryEmbolism ,
                                                                                   :pulmonaryOedema ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Aciclovir ,
                                                                                     :Esomeprazole ,
                                                                                     :Furosemide ,
                                                                                     :spironolactone ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient54 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 54" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report55
:Report55 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :LeftVentricularDysfunction ,
                                                                                   :atrialFibrillation ,
                                                                                   :dyspnoea ,
                                                                                   :hypotension ,
                                                                                   :multipleOrganDysfunctionSyndrome ,
                                                                                   :pneumothorax ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient55 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "irrelevant death" ;
          rdfs:label "Report 55" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report56
:Report56 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient56 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 56" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report57
:Report57 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetylsalicylicacid ,
                                                                                     :Metoprolol ,
                                                                                     :Omeprazole ,
                                                                                     :Pregabalin ,
                                                                                     :amlodipine ,
                                                                                     :fentanyl ,
                                                                                     :ibuprofen ,
                                                                                     :macrogol ,
                                                                                     :metamizole ,
                                                                                     :morphine ,
                                                                                     :pantoprazole ,
                                                                                     :ramipril ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#naloxone/tilidine> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient57 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 57" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report58
:Report58 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :dyspnoea ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient58 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 58" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report59
:Report59 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Arthralgia ,
                                                                                   :CardiacFailureCongestive ,
                                                                                   :Fatigue ,
                                                                                   :Nausea ,
                                                                                   :Rash ,
                                                                                   :decreasedAppetite ,
                                                                                   :vomiting ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient59 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 59" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                  :rhabdomyolysis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Acetylsalicylicacid ,
                                                                                    :Esomeprazole ,
                                                                                    :Paracetamol ,
                                                                                    :atorvastatin ,
                                                                                    :fusidicAcid ,
                                                                                    :prednisone ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report60
:Report60 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailureCongestive ,
                                                                                   :atrialFibrillation ,
                                                                                   :pleuralEffusion ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient60 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 60" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report61
:Report61 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                   :Fatigue ,
                                                                                   :hypertension ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Sertraline ,
                                                                                     :Simvastatin ,
                                                                                     :Tiotropium ,
                                                                                     :fenoterolIpratropium ,
                                                                                     :hydrochlorothiazide ,
                                                                                     :phenprocoumon ,
                                                                                     :ramipril ,
                                                                                     :salmeterol ,
                                                                                     :torasemide ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Citric_acid/potassium_bicarbonate/potassium_citrate> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient61 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 61" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report7
:Report7 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report8
:Report8 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ,
                                                                                  :wrongTechniqueInProductUsageProcess ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_medication_error> :wrongTechniqueInProductUsageProcess ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Report9
:Report9 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ejectionFractionDecreased ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with sequelae" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ReportsHavingFatalOutcome
:ReportsHavingFatalOutcome rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 6 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                           rdfs:label "Reports having fatal outcome" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ReportsHavingMetastaticNeoplasmAsIndication
:ReportsHavingMetastaticNeoplasmAsIndication rdf:type owl:NamedIndividual ,
                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Neoplasm ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                             rdfs:label "Reports having metastatic neoplasm as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ReportsHavingMetastaticThyroidCancerAsIndication
:ReportsHavingMetastaticThyroidCancerAsIndication rdf:type owl:NamedIndividual ,
                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :MetastaticThyroidCancer ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                  rdfs:label "Reports having metastatic thyroid cancer as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ReportsHavingVemurafenibAsPrimarySuspectDrug
:ReportsHavingVemurafenibAsPrimarySuspectDrug rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 35 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                              rdfs:label "Reports having Vemurafenib as primary suspect drug" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ReportsThatDidNotRecover
:ReportsThatDidNotRecover rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 10 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                          rdfs:label "Reports that did not recover" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_Australia
:Reports_from_Australia rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Australia" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                        rdfs:label "Reports from Australia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_Canada
:Reports_from_Canada rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Canada" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                     rdfs:label "Reports from Canada" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_Czech_Republic
:Reports_from_Czech_Republic rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Czech_Republic" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                             rdfs:label "Reports from Czech Republic" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_France
:Reports_from_France rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 11 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/France" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                     rdfs:label "Reports from France" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_Germany
:Reports_from_Germany rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 6 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Germany" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from Germany" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_Italy
:Reports_from_Italy rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Italy" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Reports from Italy" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_Japan
:Reports_from_Japan rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Japan" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Reports from Japan" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_Spain
:Reports_from_Spain rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Spain" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                    rdfs:label "Reports from Spain" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_United_Kingdom
:Reports_from_United_Kingdom rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_Kingdom" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                             rdfs:label "Reports from United Kingdom" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_United_States
:Reports_from_United_States rdf:type owl:NamedIndividual ,
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 26 ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_States" ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                            rdfs:label "Reports from United States" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_from_the_Netherlands
:Reports_from_the_Netherlands rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Netherlands" ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                              rdfs:label "Reports from Netherlands" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_having_cobimetinib_as_co_suspected_drug
:Reports_having_cobimetinib_as_co_suspected_drug rdf:type owl:NamedIndividual ,
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :cobinetinib ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 18 ;
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                 rdfs:label "Reports having cobimetinib as co suspected drug" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_having_everolimus_as_co_suspected_drug
:Reports_having_everolimus_as_co_suspected_drug rdf:type owl:NamedIndividual ,
                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Everolimus ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                rdfs:label "Reports having everolimus as co suspected drug" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_having_ifosfamide_as_co_suspected_drug
:Reports_having_ifosfamide_as_co_suspected_drug rdf:type owl:NamedIndividual ,
                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ifosfamide ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                rdfs:label "Reports having ifosfamide as co suspected drug" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_having_loxoprofen_as_co_suspected_drug
:Reports_having_loxoprofen_as_co_suspected_drug rdf:type owl:NamedIndividual ,
                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :loxoprofen ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                rdfs:label "Reports having loxoprofen as co suspected drug" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_having_methotrexate_as_co_suspected_drug
:Reports_having_methotrexate_as_co_suspected_drug rdf:type owl:NamedIndividual ,
                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Vemurafenib ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :methotrexate ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                  rdfs:label "Reports having methotrexate as co suspected drug" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_in_Vigibase
:Reports_in_Vigibase rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "As of 10 September 2016, there are 61 individualcase safety reports (ICSRs) of cardiac failure inassociation with vemurafenib in the WHO globaldatabase of ICSRs, VigiBase. The association has anIC value of 0.22 with an IC025 value of -0.17. Afterelimination of suspected duplicates, there are 59cases. The cases were submitted from the UnitedStates (26 cases), France (11), Germany (6), Italy(5), Japan (4), United Kingdom (2), and Australia,Canada, the Czech Republic, the Netherlands andSpain (all 1 each). The patients ranged in age from9 to 88 years with a median of 67 years in the 44reports in which this information was provided. Thegender distribution was 30 males, 24 females andfive not specified.Vemurafenib was the only drug suspected in 35 ofthe 59 cases. In the remaining 24 cases,cobimetinib was also suspected in 18 cases whileloxoprofen, everolimus and methotrexate were alsosuspected in one case each. Placebo was suspectedin two cases and both ifosfamide and a drug not yetaccepted in the WHO Drug Dictionary weresuspected in the remaining case. Concomitantdrugs were reported in 30 cases and included drugsfor treatment of cardiovascular disease (16 cases),pain management (16), thrombosis prophylaxis(12), proton pump inhibitors (11), hypolipidaemics(9), and depression (7).The indication for vemurafenib was stated in 52 ofthe 59 reports and was malignant and/or metastaticmelanoma or just melanoma in 47 cases, neoplasmin three cases and thyroid cancer, probablymetastatic, in the remaining two cases. In theseven reports where a reason for use was notstated, melanoma could be inferred in four of theseven cases.Time to onset was reported in 31 of the 59 ICSRs.It ranged from two days to 14 months with amedian of eight weeks. The outcome was stated in42 reports. The patients were reported asrecovered or recovering in 26 cases, not recoveredin 10 cases and the outcome was fatal in theremaining six reports. In the reports where theoutcome was reported as recovered or recovering,the drug was withdrawn in 13 cases, alreadystopped before onset in three cases, continued infive cases and the action taken with the drug wasunknown in five cases. In another report in whichthe outcome was unknown, the patient recoveredfrom an initial reaction while continuing to take the drug but then had a second episode after which vemurafenib was withdrawn. In the cases where the patients had not recovered, the drug was withdrawn in four cases, continued in two cases, continued for some time and then withdrawn in two cases and the action taken with the drug was unknown in the remaining two cases. In the six cases where the outcome was fatal, the drug was withdrawn in three cases and the action taken with the drug was unknown in the remaining three cases. The cause of death was disease progression in one case and complications of heart failure in another case but the cause of death in the remaining four cases was not stated. Other reactions were described in 36 of the reports. These reactions included other cardiac reactions in 13 cases including myocarditis/pericarditis/cardiomyopathy (5 reports) and atrial fibrillation (4), pulmonary reactions in 10 cases including pleural effusion (4), renal impairment and failure in 10 cases, infections in nine cases including pneumonia (7), dyspnoea (8 cases), skin reactions (5 cases), joint and muscle pain (5 cases) and fatigue/malaise (5 cases)." ;
                     rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_atrial_fibrillation
:Reports_with_atrial_fibrillation rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :atrialFibrillation ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                  rdfs:label "Reports with atrial fibrillation" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_dyspnoea
:Reports_with_dyspnoea rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :dyspnoea ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 8 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                       rdfs:label "Reports with dyspnoea" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_joint_and_muscle_pain
:Reports_with_joint_and_muscle_pain rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Joint_pain ,
                                                                                                             :Muscle_pain ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                    rdfs:label "Reports with joint and muscle pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_pleural_effusion
:Reports_with_pleural_effusion rdf:type owl:NamedIndividual ,
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :pleuralEffusion ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                               rdfs:label "Reports with pleural effusion" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_pneumonia
:Reports_with_pneumonia rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :pneumonia ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 7 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                        rdfs:label "Reports with pneumonia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_renal_impairement_and_failure
:Reports_with_renal_impairement_and_failure rdf:type owl:NamedIndividual ,
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :renalFailure ,
                                                                                                                     :renalImpairment ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 10 ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                            rdfs:label "Reports with renal impairement and failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_skin_reactions
:Reports_with_skin_reactions rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :skin_reaction ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                             rdfs:label "Reports with skin reactions" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Sertraline
:Sertraline rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AB06" ;
            rdfs:label "sertraline" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Simvastatin
:Simvastatin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA01" ;
             rdfs:label "simvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Sodium
:Sodium rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A12CA" ;
        rdfs:label "sodium" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Tinzaparin
:Tinzaparin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AB10 " ;
            rdfs:label "tinzaparin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Tiotropium
:Tiotropium rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03BB04" ;
            rdfs:label "tiotropium" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Uppsala_monitoring_center
:Uppsala_monitoring_center rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/ns/prov#Organization> ;
                           rdfs:label "Uppsala monitoring center" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Vemurafenib
:Vemurafenib rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :BRAFV600PositiveMetastaticOrUnresectableMelanoma ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Mechanism_of_vemurafenib ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Alopecia ,
                                                                                      :Arthralgia ,
                                                                                      :CutaneousSquamousCellCarcinoma ,
                                                                                      :Fatigue ,
                                                                                      :Nausea ,
                                                                                      :PhotosensitivityReaction ,
                                                                                      :Pruritus ,
                                                                                      :Rash ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01EC01" ;
             rdfs:label "Vemurafenib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Vemurafenib_and_cardiac_failure
:Vemurafenib_and_cardiac_failure rdf:type owl:NamedIndividual ,
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Pharmacovigilance_Signal_Report> ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_author> :Dr._Ian_Boyd ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_signal> :PV_Signal ;
                                 mp:publishedBy :Uppsala_monitoring_center ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "01/07/2018"^^xsd:date ;
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_overall_conclusion> "causal association most probable" ;
                                 rdfs:label "Vemurafenib and cardiac failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Warning_information_for_dabrafenib
:Warning_information_for_dabrafenib rdf:type owl:NamedIndividual ,
                                             <http://purl.obolibrary.org/obo/OAE_0001197> ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :LeftVentricularDysfunction ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :trametinib ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :dabrafenib ;
                                    mp:references :Ref.6 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The product information for another BRAF enzyme inhibitor, dabrafenib, has a warning that dabrafenib in combination with trametinib has been reported to decrease left ventricular ejection fraction (LVEF).6 It also lists ejection fraction decreased as a common adverse reaction but this adverse reaction arises from combination with trametinib and not dabrafenib alone." ;
                                    rdfs:label "Product information for dabrafenib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Zolpidem
:Zolpidem rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05CF02" ;
          rdfs:label "zolpidem" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#abdominalDiscomfort
:abdominalDiscomfort rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R10.9" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10000059 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Abdominal discomfort" ;
                     rdfs:label "abdominal discomfort" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#abdominalDistension
:abdominalDistension rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R14.0" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10000060 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Abdominal distension" ;
                     rdfs:label "abdominal distension" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#acuteCoronarySyndrome
:acuteCoronarySyndrome rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I24.9" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10051592 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Acute coronary syndrome" ;
                       rdfs:label "acute coronary syndrome" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#acuteKidneyInjury
:acuteKidneyInjury rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N17.9" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10069339 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Acute kidney injury" ;
                   rdfs:label "acute kidney injury" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#acuteRespiratoryDistressSyndrome
:acuteRespiratoryDistressSyndrome rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J80" ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10001052 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Acute respiratory distress syndrome" ;
                                  rdfs:label "acute respiratory distress syndrome" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#age_of_patients_that_are_likely_to_develop_cardiac_failure
:age_of_patients_that_are_likely_to_develop_cardiac_failure rdf:type owl:NamedIndividual ,
                                                                     <http://purl.obolibrary.org/obo/OAE_0000117> ;
                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "This conclusion is strengthened by the observation that nine of the 59 patients were aged 50 years or less, an age group in which cardiac failure is unlikely to occur through natural causes." ;
                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 50 ;
                                                            rdfs:label "age of patients that are likely to develop cardiac failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#amlodipine
:amlodipine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08CA01" ;
            rdfs:label "amlodipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#amoxicillinClavulanicAcid
:amoxicillinClavulanicAcid rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "J01CR02" ;
                           rdfs:label "amoxicillin clavulanic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#anginaPectoris
:anginaPectoris rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I20.9" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10002383 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Angina pectoris" ;
                rdfs:label "angina pectoris" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ascorbicAcid
:ascorbicAcid rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A11GA01" ;
              rdfs:label "ascorbic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#asthenia
:asthenia rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R53.1" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10003549 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Asthenia" ;
          rdfs:label "asthenia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#atorvastatin
:atorvastatin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA05" ;
              rdfs:label "atorvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#atrialFibrillation
:atrialFibrillation rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I48 " ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10003658 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Atrial fibrillation" ;
                    rdfs:label "atrial fibrillation" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#backpain
:backpain rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M54.5" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10003988 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Back pain" ;
          rdfs:label "backpain" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#bacterialPericarditis
:bacterialPericarditis rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I30.1" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10004050 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Bacterial pericarditis" ;
                       rdfs:label "bacterial pericarditis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#benzonatate
:benzonatate rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R05DB01" ;
             rdfs:label "benzonatate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#betahistine
:betahistine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N07CA01" ;
             rdfs:label "betahistine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#blister
:blister rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "S90.821A" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10005191 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Blister" ;
         rdfs:label "blister" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#bloodBilirubinIncreased
:bloodBilirubinIncreased rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E80.7" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10005364 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Blood bilirubin increased" ;
                         rdfs:label "blood bilirubin increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#bloodCreatinineIncreased
:bloodCreatinineIncreased rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R79.89" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10005483 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Blood creatinine increased" ;
                          rdfs:label "blood creatinine increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#bloodUreaIncreased
:bloodUreaIncreased rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R79.89" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10005851 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Blood urea increased" ;
                    rdfs:label "blood urea increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#breastPain
:breastPain rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N64.4" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10006298 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Breast pain" ;
            rdfs:label "breast pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#breastSwelling
:breastSwelling rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N63.0" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10006312 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Breast swelling" ;
                rdfs:label "breast swelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#bronchitis
:bronchitis rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J40" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10006451 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Bronchitis" ;
            rdfs:label "bronchitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#bumetanide
:bumetanide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA02" ;
            rdfs:label "bumetanide" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#calcium
:calcium rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A12AA" ;
         rdfs:label "calcium" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#carboplatin
:carboplatin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01XA02" ;
             rdfs:label "carboplatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#cardiacDisorder
:cardiacDisorder rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I51.9" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10061024 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cardiac disorder" ;
                 rdfs:label "cardiac disorder" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#cardiomyopathy
:cardiomyopathy rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I42.9" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10007636 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cardiomyopathy" ;
                rdfs:label "cardiomyopathy" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#carvedilol
:carvedilol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AG02" ;
            rdfs:label "carvedilol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#celecoxib
:celecoxib rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M01AH01 " ;
           rdfs:label "celecoxib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#cetirizine
:cetirizine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R06AE07" ;
            rdfs:label "cetirizine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#chills
:chills rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R68.83" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10008531 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Chills" ;
        rdfs:label "chills" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#chronicObstructivePulmonaryDisease
:chronicObstructivePulmonaryDisease rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J44.9" ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10009033 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Chronic obstructive pulmonary disease" ;
                                    rdfs:label "chronic obstructive pulmonary disease" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ciclosporin
:ciclosporin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L04AD01" ;
             rdfs:label "ciclosporin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#cobinetinib
:cobinetinib rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Mechanism_of_cobimetinib ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01XE38" ;
             rdfs:label "cobimetinib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#codeineGuaifenesin
:codeineGuaifenesin rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R05CA03" ;
                    rdfs:label "codeine guaifenesin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#conclusion
:conclusion rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Conclusion> ;
            mp:references :Ref.7 ,
                          :Ref.8 ,
                          :Ref.9 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Case reports in VigiBase suggest that there is a signal for the association of vemurafenib and cardiac failure. There are 59 reports of cardiac failure and vemurafenib was the only drug suspected in 35 of the cases. In the remaining 24 cases, cobimetinib was also suspected in 18 cases. All 11 reports from France had both vemurafenib and cobimetinib as suspected drugs as did three reports from Germany, two from Italy and one each from the US and the Netherlands. Cobimetinib is also a kinase inhibitor but cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. In the product information for cobimetinib, there is a warning concerning both the possibility of QT prolongation and advice that a decrease in LVEF from baseline has been reported in patients receiving cobimetinib. Median time to initial onset of events was four months (1-13 months).7 It is therefore possible that in those reports where both vemurafenib and cobimetinib are suspected drugs, cobimetinib might be a more likely suspect. In the nine reports in which the patient recovered, both cobimetinib and vemurafenib were withdrawn in four cases, cobimetinib was withdrawn and vemurafenib continued in four cases and cobimetinib withdrawn and the action taken with vemurafenib unknown in the other case. This dechallenge information appears to favour cobimetinib as the more likely drug. In the five reports where the patient had not recovered, both drugs were withdrawn in two cases, both drugs were continued then stopped in one case, vemurafenib was continued and cobimetinib withdrawn in one case and vemurafenib continued and then stopped and cobimetinib withdrawn in the remaining case. This information appears to slightly favour vemurafenib as the most likely drug. In the remaining six cases in which there was another suspected drug, those drugs mostly do not appear to be a compelling cause. Methotrexate, loxoprofen and everolimus were suspected in one case each. Cardiac failure is not mentioned as an adverse effect of methotrexate and it was withdrawn six months before onset of cardiac failure and does not appear to be a plausible cause. Similarly, cardiac failure is not mentioned as an adverse effect of loxoprofen and it was withdrawn three months before onset of cardiac failure and also does not appear to be a plausible cause. On the other hand, the product information lists congestive cardiac failure as an uncommon adverse effect for everolimus.8 There is no information on time to onset and the outcome was fatal so it is difficult to make an attribution in this case. In another report, both ifosfamide and a drug not yet accepted in the WHO Drug Dictionary were suspected. There is no information on the drug not yet accepted but like many anticancer agents, ifosfamide is cardiotoxic but the delay of four months between the withdrawal of these two drugs and the onset of cardiac failure would appear to favour vemurafenib as the most likely cause. Placebo was suspected in the two remaining cases and it is an unlikely cause. Time to onset was reported in 31 of the 59 ICSRs. It ranged from two days to 14 months with a median of eight weeks. This appears to be consistent with other case series. As noted above, cardiac failure in association with cobimetinib had a median time to initial onset of four months with a range of 1-13 months.7 A case series of cardiac failure in association with tumour necrosis factor antagonists had a median time to onset of 3.5 months with a range of one day to two years.9 The outcome was stated in 42 reports. The patients were reported as recovered or recovering in 26 cases, not recovered in 10 cases and the outcome was fatal in the remaining six reports. In the reports where the outcome was reported as recovered or recovering, the drug was withdrawn in 13 cases, already stopped before onset in three cases, continued in five cases and the action taken with the drug was unknown in five cases. In another report in which the outcome was unknown, the patient recovered from an initial reaction but then had a second episode while continuing to take vemurafenib after which the drug was withdrawn. The 13 cases of recovery after withdrawal of vemurafenib are strong evidence of the drug as the cause. Concomitant drugs were reported in 30 cases and included drugs used in a patient population which might be at risk of cardiac failure due to the presence of cardiovascular disease in about half of those cases. In addition, there are an additional five reports in which pre-existing cardiovascular disease is mentioned and these patients are at increased risk of developing cardiac failure. It is also possible that concomitant cardiac reactions may have caused or made a contribution to the cause of the cardiac failure. There are no reports in the literature of cardiac failure in association with vemurafenib but although cardiac failure may have other possible causes in some patients in this series, the use of vemurafenib appears the most likely reason. This conclusion is strengthened by the observation that nine of the 59 patients were aged 50 years or less, an age group in which cardiac failure is unlikely to occur through natural causes." ;
            rdfs:label "conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#confusionalState
:confusionalState rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "F05" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10010305 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Confusional state" ;
                  rdfs:label "confusional state" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#dabrafenib
:dabrafenib rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01XE23 " ;
            rdfs:label "dabrafenib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#death
:death rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G93. 82" ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10011906 ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Death" ;
       rdfs:label "death|mortality" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#decreasedAppetite
:decreasedAppetite rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R63.0" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10061428 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Decreased appetite" ;
                   rdfs:label "decreased appetite" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#dehydration
:dehydration rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E86.0" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012174 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Dehydration" ;
             rdfs:label "dehydration" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#dexamethasone
:dexamethasone rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "S02BA06" ;
               rdfs:label "dexamethasone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#diarrhoea
:diarrhoea rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R19.7" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012735 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Diarrhoea" ;
           rdfs:label "diarrhoea" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#diffuseAlveolarDamage
:diffuseAlveolarDamage rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J84.09" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10060902 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Diffuse alveolar damage" ;
                       rdfs:label "diffuse alveolar damage" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#domperidone
:domperidone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A03FA03 " ;
             rdfs:label "domperidone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#duloxetine
:duloxetine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AX21 " ;
            rdfs:label "duloxetine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#dutasteride
:dutasteride rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G04CB02" ;
             rdfs:label "dutasteride" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#dyspnoea
:dyspnoea rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R06.00" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013968 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Dyspnoea" ;
          rdfs:label "dyspnoea" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ejectionFractionDecreased
:ejectionFractionDecreased rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I50.2" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10050528 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Ejection fraction decreased" ;
                           rdfs:label "Ejection Fraction Decreased" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#electrocardiogramQTProlonged
:electrocardiogramQTProlonged rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I45.81" ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10014387 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Electrocardiogram QT prolonged" ;
                              rdfs:label "electrocardiogram QT prolonged" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#electrolyteImbalance
:electrolyteImbalance rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E87.8" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10014418 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Electrolyte imbalance" ;
                      rdfs:label "electrolyte imbalance" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#erythemaNodosum
:erythemaNodosum rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L52" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10015226 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Erythema nodosum" ;
                 rdfs:label "erythema nodosum" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#eyePruritus
:eyePruritus rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "H57.8" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10052140 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Eye pruritus" ;
             rdfs:label "eye pruritus" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#fenoterolIpratropium
:fenoterolIpratropium rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03AL01 " ,
                                                                                   "R03BB01" ;
                      rdfs:label "fenoterol ipratropium" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#fentanyl
:fentanyl rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N01AH01" ;
          rdfs:label "fentanyl" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#fishOil
:fishOil rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AX06 " ;
         rdfs:label "fish oil" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#fluidRetention
:fluidRetention rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E87.7" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10016807 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Fluid retention" ;
                rdfs:label "fluid retention" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#fluticasone
:fluticasone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D07AC17" ;
             rdfs:label "fluticasone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#fusidicAcid
:fusidicAcid rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D06AX01" ;
             rdfs:label "fusidic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#gabapentin
:gabapentin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AX12" ;
            rdfs:label "gabapentin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#generalPhysicalHealthDeterioration
:generalPhysicalHealthDeterioration rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R53.81" ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10049438 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "General physical health deterioration" ;
                                    rdfs:label "general physical health deterioration" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#generalisedOedema
:generalisedOedema rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R60.1" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10018092 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Generalised oedema" ;
                   rdfs:label "generalised oedema" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#glyceryltrinitrate
:glyceryltrinitrate rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01DA02 " ;
                    rdfs:label "glyceryltrinitrate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#haemolyticUraemicSyndromeAcute
:haemolyticUraemicSyndromeAcute rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "D59.3" ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10018932 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Haemolytic uraemic syndrome" ;
                                rdfs:label "haemolytic uraemic syndrome acute" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#headache
:headache rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R51" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019211 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Headache" ;
          rdfs:label "headache" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#heartRateIncreased
:heartRateIncreased rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R00.0" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019303 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Heart rate increased" ;
                    rdfs:label "heart rate increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#hepaticEnzymeIncreased
:hepaticEnzymeIncreased rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R94.5" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10060795 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hepatic enzyme increased" ;
                        rdfs:label "hepatic enzyme increased" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#hydrochlorothiazide
:hydrochlorothiazide rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03AA03" ;
                     rdfs:label "hydrochlorothiazide" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#hydrocodoneParacetamol
:hydrocodoneParacetamol rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02" ;
                        rdfs:label "hydrocodone paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#hydroxyzine
:hydroxyzine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BB01" ;
             rdfs:label "hydroxyzine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#hyperkeratosis
:hyperkeratosis rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L85.9" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020649 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hyperkeratosis" ;
                rdfs:label "hyperkeratosis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#hypertension
:hypertension rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I10" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020772 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypertension" ;
              rdfs:label "hypertension" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#hypotension
:hypotension rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I95.9" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10021097 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypotension" ;
             rdfs:label "hypotension" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ibuprofen
:ibuprofen rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01EB16" ;
           rdfs:label "ibuprofen" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#insulinAspart
:insulinAspart rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10AB05" ;
               rdfs:label "insulin aspart" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#insulinGlargine
:insulinGlargine rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10AE04" ;
                 rdfs:label "insulin glargine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#insulinHuman
:insulinHuman rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10AC01" ;
              rdfs:label "insulin human" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#insulinLispro
:insulinLispro rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10AB04" ;
               rdfs:label "insulin lispro" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#interstitialLungDisease
:interstitialLungDisease rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J84.9" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10022611 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Interstitial lung disease" ;
                         rdfs:label "interstitial lung disease" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#introduction
:introduction rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction> ;
              mp:references :Ref.1 ,
                            :Ref.2 ,
                            :Ref.3 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Vemurafenib is a low molecular weight, orallyavailable, inhibitor of BRAF serine-threonine kinase(a member of the Raf kinase family of growthsignal transduction protein kinases). Mutations inthe BRAF gene which substitute the valine atamino acid position 600 result in constitutivelyactivated BRAF proteins, which can cause cellproliferation in the absence of growth factors that would normally be required for proliferation.1Before taking vemurafenib, patients must haveBRAF V600 mutation-positive tumour statusconfirmed by a validated test. It is one of the medications widely known as tyrosine kinaseinhibitors (TKIs) but should be referred to as protein kinase inhibitors because although theearliest drugs in this class were TKIs, they can now be further categorized based upon the amino acid that they phosphorylate: serine, threonine or tyrosine. Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF V600mutation-positive unresectable or metastatic melanoma. The most common adverse drug reactions (ADR) (>30%) reported with vemurafenib include arthralgia, fatigue, rash, photosensitivity reaction, nausea, alopecia andpruritus. Cutaneous squamous cell carcinoma(CuSCC) was very commonly reported and was most commonly treated by local excision. There are warnings in the product information concerningthe possible occurrence of severe hypersensitivity and dermatological reactions, QT prolongation, serious ophthalmologic reactions, non-cuSCC, new primary melanomas, liver laboratory abnormalitiesand mild to severe photosensitivity.1Cardiac failure is a condition in which the heart isunable to pump an adequate amount of blood tomeet the metabolic and physiological needs of thebody. Cases are often classified using the fourstages according to the New York HeartAssociation.2 Basic requirements for use of theterm, according to CIOMS, include any three of thefollowing:• dependent oedema,• raised jugular venous pressure orhepatomegaly in the absence of liver disease,• signs of pulmonary congestion or effusion,• rapid heart-rate (>100 beats/min) orgallop rhythm,• enlarged heart,• dyspnoea in the absence of pulmonary disease,or• ejection fraction less than 35 per cent.2A large number of drugs have been implicated as acause of cardiac failure. These include anticanceragents such as anthracyclines, mitoxantrone, cyclophosphamide, fluorouracil, capecitabine andtrastuzumab; immunomodulating drugs such asinterferon-α-2, interleukin-2, infliximab andetanercept; antidiabetic drugs such as rosiglitazone, pioglitazone and troglitazone;antimigraine drugs such as ergotamine and methysergide; appetite suppressants such asfenfluramine, dexfenfluramine and phentermine;tricyclic antidepressants; antipsychotic drugs suchas clozapine; antiparkinsonian drugs such aspergolide and cabergoline; NSAIDs,glucocorticoids; and antifungal drugs such asitraconazole and amphotericin B.3In WHO-ART, cardiac failure is a preferred termwhile in MedDRA, the terms which are coded ascardiac failure in WHO-ART such as cardiac failureacute and cardiac failure congestive, ejectionfraction decreased and left ventricular dysfunctionare separate preferred terms. These are all analysedtogether in this assessment as cardiac failure." ;
              rdfs:label "introduction" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#isosorbide_mononitrate
:isosorbide_mononitrate rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01DA14" ;
                        rdfs:label "isosorbide mononitrate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#jointSwelling
:jointSwelling rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M25.40" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10023232 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Joint swelling" ;
               rdfs:label "joint swelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#lamotrigine
:lamotrigine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AX09" ;
             rdfs:label "lamotrigine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#leflunomide
:leflunomide rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L04AA13" ;
             rdfs:label "leflunomide" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#levetiracetam
:levetiracetam rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AX14" ;
               rdfs:label "levetiracetam" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#levosulpiride
:levosulpiride rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AL07 " ;
               rdfs:label "levosulpiride" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#levothyroxine
:levothyroxine rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "H03AA01" ;
               rdfs:label "levothyroxine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#lidocaine
:lidocaine rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D04AB01 " ;
           rdfs:label "lidocaine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#liverFunctionTestAbnormal
:liverFunctionTestAbnormal rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R94.5" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10024690 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Liver function test abnormal" ;
                           rdfs:label "liver function test abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#liverLaboratoryAbnormalities
:liverLaboratoryAbnormalities rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R94.5" ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10024670 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Liver disorder" ;
                              rdfs:label "liver laboratory abnormalities" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#loratadine
:loratadine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R06AX13" ;
            rdfs:label "loratadine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#lorazepam
:lorazepam rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05BA06" ;
           rdfs:label "lorazepam" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#lowerRespiratoryTractInfection
:lowerRespiratoryTractInfection rdf:type owl:NamedIndividual ,
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J22" ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10024968 ;
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Lower respiratory tract infection" ;
                                rdfs:label "lower respiratory tract infection" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#loxoprofen
:loxoprofen rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M01AE‎ " ;
            rdfs:label "loxoprofen" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#macrogol
:macrogol rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A06AD15 " ;
          rdfs:label "macrogol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#melanoma
:melanoma rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C43.9" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10053571 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Melanoma" ;
          rdfs:label "melanoma" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#mesalazine
:mesalazine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A07EC02 " ;
            rdfs:label "mesalazine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#metamizole
:metamizole rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02BB02" ;
            rdfs:label "metamizole" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#metastasesToLiver
:metastasesToLiver rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C78.7" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10027457 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Metastases to liver" ;
                   rdfs:label "metastases to liver" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#metastaticMalignantMelanoma
:metastaticMalignantMelanoma rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C43.9" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10027480 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Metastatic malignant melanoma" ;
                             rdfs:label "metastatic malignant melanoma" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#methotrexate
:methotrexate rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01BA01" ;
              rdfs:label "methotrexate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#methylprednisolone
:methylprednisolone rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D07AA01" ;
                    rdfs:label "methylprednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#metolazone
:metolazone rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03BA08" ;
            rdfs:label "metolazone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#metronidazole
:metronidazole rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A01AB17" ;
               rdfs:label "metronidazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#mirtazapine
:mirtazapine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AX11" ;
             rdfs:label "mirtazapine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#morphine
:morphine rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02AA01" ;
          rdfs:label "morphine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#mucosalInflammation
:mucosalInflammation rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "K52.89" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028116 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Mucosal inflammation" ;
                     rdfs:label "mucosal inflammation" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#multipleOrganDysfunctionSyndrome
:multipleOrganDysfunctionSyndrome rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R65.2" ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10077361 ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Multiple organ dysfunction syndrome" ;
                                  rdfs:label "multiple organ dysfunction syndrome" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#musculoskeletalChestPain
:musculoskeletalChestPain rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R07.89" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10050819 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Musculoskeletal chest pain" ;
                          rdfs:label "musculoskeletal chest pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#musculoskeletalPain
:musculoskeletalPain rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M79.1" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028391 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Musculoskeletal pain" ;
                     rdfs:label "musculoskeletal pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#mycophenolicAcid
:mycophenolicAcid rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L04AA06 " ;
                  rdfs:label "mycophenolic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#myocardialInfarction
:myocardialInfarction rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I21.9" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028596 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Myocardial infarction" ;
                      rdfs:label "myocardial infarction" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#myocardialIschaemia
:myocardialIschaemia rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J96.00" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028600 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Myocardial ischaemia" ;
                     rdfs:label "myocardial ischaemia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#myocarditis
:myocarditis rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I51.4" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10028606 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Myocarditis" ;
             rdfs:label "myocarditis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#nadroparin
:nadroparin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AB06" ;
            rdfs:label "nadroparin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#naproxen
:naproxen rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M01AE02 " ;
          rdfs:label "naproxen" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#neoplasmProgression
:neoplasmProgression rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C80.1" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10061309 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Neoplasm progression" ;
                     rdfs:label "neoplasm progression" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#nicotine
:nicotine rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N07BA01" ;
          rdfs:label "nicotine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#nippleSwelling
:nippleSwelling rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N64.59" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10058680 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Nipple swelling" ;
                rdfs:label "nipple swelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#oedema
:oedema rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R60.9" ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10030095 ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Oedema" ;
        rdfs:label "oedema" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ondansetron
:ondansetron rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A04AA01 " ;
             rdfs:label "ondansetron" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ophthalmologicReactions
:ophthalmologicReactions rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10030045 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Ocular infections, inflammations and associated manifestations" ;
                         rdfs:label "ophthalmologic reactions" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#opportunisticInfection
:opportunisticInfection rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "B99.8" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10030901 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Opportunistic infection" ;
                        rdfs:label "opportunistic infection" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#oropharyngealPain
:oropharyngealPain rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R07.0" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10068319 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Oropharyngeal pain" ;
                   rdfs:label "oropharyngeal pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#orthopnoea
:orthopnoea rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R06.01" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10031123 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Orthopnoea" ;
            rdfs:label "orthopnoea" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#oxycodone
:oxycodone rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02AA05 " ;
           rdfs:label "oxycodone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#oxygen
:oxygen rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "V03AN01" ;
        rdfs:label "oxygen" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pancytopenia
:pancytopenia rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "D61.81" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10033661 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pancytopenia" ;
              rdfs:label "pancytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pantoprazole
:pantoprazole rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC02" ;
              rdfs:label "pantoprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#paroxetine
:paroxetine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AB05" ;
            rdfs:label "paroxetine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pericardialEffusion
:pericardialEffusion rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I31.3" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10034474 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pericardial effusion" ;
                     rdfs:label "pericardial effusion" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pericarditis
:pericarditis rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I30" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10034484 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pericarditis" ;
              rdfs:label "pericarditis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#phenprocoumon
:phenprocoumon rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AA04" ;
               rdfs:label "phenprocoumon" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#placebo
:placebo rdf:type owl:NamedIndividual ;
         rdfs:label "placebo" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pleuralEffusion
:pleuralEffusion rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J90" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10035598 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pleural effusion" ;
                 rdfs:label "pleural effusion" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pleuropericarditis
:pleuropericarditis rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I30.9" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10059361 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pleuropericarditis" ;
                    rdfs:label "pleuropericarditis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pneumonia
:pneumonia rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J18.9" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10035664 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pneumonia" ;
           rdfs:label "pneumonia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pneumonitis
:pneumonitis rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J69.0" ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10035742 ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pneumonitis" ;
             rdfs:label "pneumonitis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pneumothorax
:pneumothorax rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J93.9" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10035759 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pneumothorax" ;
              rdfs:label "pneumothorax" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#polymeraseChainReaction
:polymeraseChainReaction rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10050967 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Polymerase chain reaction" ;
                         rdfs:label "polymerase chain reaction" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#poorQualitySleep
:poorQualitySleep rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G47.9" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10062519 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Poor quality sleep" ;
                  rdfs:label "poor quality sleep" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#potassiumAspartate
:potassiumAspartate rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A12BA30 " ;
                    rdfs:label "potassium aspartate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#prasugrel
:prasugrel rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AC22 " ;
           rdfs:label "prasugrel" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#prednisolone
:prednisolone rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A07EA01" ;
              rdfs:label "prednisolone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#prednisone
:prednisone rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "H02AB07" ;
            rdfs:label "prednisone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#prochlorperazine
:prochlorperazine rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AB04" ;
                  rdfs:label "prochlorperazine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#productiveCough
:productiveCough rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R05" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10036790 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Productive cough" ;
                 rdfs:label "productive cough" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pulmonaryAlveolarHaemorrhage
:pulmonaryAlveolarHaemorrhage rdf:type owl:NamedIndividual ,
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R04.89" ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037313 ;
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pulmonary alveolar haemorrhage" ;
                              rdfs:label "pulmonary alveolar haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pulmonaryEmbolism
:pulmonaryEmbolism rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I26.99" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037377 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pulmonary embolism" ;
                   rdfs:label "pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pulmonaryOedema
:pulmonaryOedema rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J81.0" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037423 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pulmonary oedema" ;
                 rdfs:label "pulmonary oedema" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#pyrexia
:pyrexia rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R50.9" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037660 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pyrexia" ;
         rdfs:label "pyrexia" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ramipril
:ramipril rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09AA05" ;
          rdfs:label "ramipril" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#renalFailure
:renalFailure rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N18.9" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10038435 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Renal failure" ;
              rdfs:label "renal failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#renalFunctionTestAbnormal
:renalFunctionTestAbnormal rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R94.4" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10061480 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Renal function test abnormal" ;
                           rdfs:label "renal function test abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#renalImpairment
:renalImpairment rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N28.9" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10062237 ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Renal impairment" ;
                 rdfs:label "renal impairment" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#respiratoryDistress
:respiratoryDistress rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R06.03" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10038687 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Respiratory distress" ;
                     rdfs:label "respiratory distress" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#respiratoryFailure
:respiratoryFailure rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "J96.00" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10038695 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Respiratory failure" ;
                    rdfs:label "respiratory failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#rhabdomyolysis
:rhabdomyolysis rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "M62.82" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039020 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Rhabdomyolysis" ;
                rdfs:label "rhabdomyolysis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#rilmazafone
:rilmazafone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             rdfs:label "rilmazafone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#risperidone
:risperidone rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05AX08" ;
             rdfs:label "risperidone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#salbutamol
:salbutamol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03AC02" ;
            rdfs:label "salbutamol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#salmeterol
:salmeterol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03AC12" ;
            rdfs:label "salmeterol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#seizure
:seizure rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "G40.909" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10039906 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Seizure" ;
         rdfs:label "seizure" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#serenoaRepens
:serenoaRepens rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "V03AX" ;
               rdfs:label "serenoa repens" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#shuntInfection
:shuntInfection rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "T85.79XA" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10058028 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Shunt infection" ;
                rdfs:label "shunt infection" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#skin_reaction
:skin_reaction rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10040914 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Skin reaction" ;
               rdfs:label "skin reaction" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#solifenacin
:solifenacin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G04BD08" ;
             rdfs:label "solifenacin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#spironolactone
:spironolactone rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03DA01" ;
                rdfs:label "spironolactone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#summary
:summary rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Vemurafenib is a low molecular weight, orallyavailable, inhibitor of BRAF serine-threonine kinase(a member of the Raf kinase family of growth signaltransduction protein kinases). It is one of themedications widely known as tyrosine kinaseinhibitors (TKIs) but should be referred to asprotein kinase inhibitors (PKIs). Vemurafenib isindicated in monotherapy for the treatment of adultpatients with BRAF V600 mutation-positiveunresectable or metastatic melanoma.In the WHO global database of individual casesafety reports (ICSRs), VigiBase there are currently(10 September 2016) 61 ICSRs of cardiac failure inassociation with vemurafenib. After elimination ofsuspected duplicates, there are 59 ICSRs of cardiacfailure. Vemurafenib was the only drug suspected in35 cases. Time to onset was reported in 31 casesand ranged from two days to 14 months with amedian of eight weeks. The outcome was stated in42 reports. The patients were reported as recoveredor recovering in 26 cases, not recovered in 10 casesand the outcome was fatal in the remaining sixreports. In the reports where the outcome wasreported as recovered or recovering, the drug waswithdrawn in 13 cases. The cases reported asrecovered or recovering after vemurafenibwithdrawal are highly suggestive of a drug-inducedeffect.In conclusion, although cardiac failure may haveother possible causes in some patients in this series,the use of vemurafenib appears the most likelyreason." ;
         rdfs:label "summary" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#sunburn
:sunburn rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L55.0" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10042496 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Sunburn" ;
         rdfs:label "sunburn" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#tacrolimus
:tacrolimus rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D11AH01" ;
            rdfs:label "tacrolimus" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#tamsulosin
:tamsulosin rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G04CA02" ;
            rdfs:label "tamsulosin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#temozolomide
:temozolomide rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01AX03" ;
              rdfs:label "temozolomide" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#teneligliptin
:teneligliptin rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BH08" ;
               rdfs:label "teneligliptin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#thiocticAcid
:thiocticAcid rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A16AX01" ;
              rdfs:label "thioctic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#time_to_onset_for_TNF_antagonists_and_cardiac_failure
:time_to_onset_for_TNF_antagonists_and_cardiac_failure rdf:type owl:NamedIndividual ,
                                                                <http://www.w3.org/2006/time#DurationDescription> ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A case series of cardiac failure in association with tumour necrosis factor antagonists had a median time to onset of 3.5 months with a range of one day to two years." ;
                                                       rdfs:label "time to onset for TNF antagonists and cardiac failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#time_to_onset_for_cobimetinib_and_cardiac_failure
:time_to_onset_for_cobimetinib_and_cardiac_failure rdf:type owl:NamedIndividual ,
                                                            <http://www.w3.org/2006/time#DurationDescription> ;
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "As noted above, cardiac failure in association with cobimetinib had a median time to initial onset of four months with a range of 1-13 months" ;
                                                   rdfs:label "time to onset for cobimetinib and cardiac failure" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#tocopherol
:tocopherol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A11HA03" ;
            rdfs:label "tocopherol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#tolterodine
:tolterodine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G04BD07" ;
             rdfs:label "tolterodine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#topirimate
:topirimate rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N03AX11" ;
            rdfs:label "topirimate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#torasemide
:torasemide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA04" ;
            rdfs:label "torasemide" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#toxicEpidermalNecrolysis
:toxicEpidermalNecrolysis rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L51.2" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10044223 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Toxic epidermal necrolysis" ;
                          rdfs:label "toxic epidermal necrolysis" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#toxicityToVariousAgents
:toxicityToVariousAgents rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "T65" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10070863 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Toxicity to various agents" ;
                         rdfs:label "toxicity to various agents" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#tramadol
:tramadol rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02AX02" ;
          rdfs:label "tramadol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#trametinib
:trametinib rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01EE01" ;
            rdfs:label "trametinib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#urinaryTractInfection
:urinaryTractInfection rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "N39.0" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10046571 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Urinary tract infection" ;
                       rdfs:label "urinary tract infection" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#verapamil
:verapamil rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08DA01 " ;
           rdfs:label "verapamil" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#vincristine
:vincristine rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01CA02 " ;
             rdfs:label "vincristine" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#visualImpairment
:visualImpairment rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "H54.7" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10047571 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Visual impairment" ;
                  rdfs:label "visual impairment" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#vitaminb12
:vitaminb12 rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B03BA01" ;
            rdfs:label "vitamin b12" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#vitamins
:vitamins rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A11" ;
          rdfs:label "vitamins" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#vomiting
:vomiting rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R11.10" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10047700 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Vomiting" ;
          rdfs:label "vomiting" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#warfarin
:warfarin rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B01AA03" ;
          rdfs:label "warfarin" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#wrongTechniqueInProductUsageProcess
:wrongTechniqueInProductUsageProcess rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Medication_Errors> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10076573 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Wrong technique in product usage process" ;
                                     rdfs:label "product misuse" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#zopiclone
:zopiclone rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05CF01" ;
           rdfs:label "zopiclone" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#δδ
:δδ rdf:type owl:NamedIndividual ,
             <http://purl.obolibrary.org/obo/OAE_0001182> ;
    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ,
                                                                   :cobinetinib ;
    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In the nine reports in which the patient recovered, both cobimetinib and vemurafenib were withdrawn in four cases, cobimetinib was withdrawn and vemurafenib continued in four cases and cobimetinib withdrawn and the action taken with vemurafenib unknown in the other case. This dechallenge information appears to favour cobimetinib as the more likely drug." ;
    rdfs:label "Dechallenge information favoring cobimetinib" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Citric_acid/potassium_bicarbonate/potassium_citrate
<http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Citric_acid/potassium_bicarbonate/potassium_citrate> rdf:type owl:NamedIndividual ,
                                                                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A09AB04 " ,
                                                                                                                                                                                              "A12BA30" ,
                                                                                                                                                                                              "B05XA06" ;
                                                                                                                                 rdfs:label "Citric acid/potassium bicarbonate/potassium citrate" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#IC_(Information_Component)_of_Vemurafenib_in_Vigibas
<http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#IC_(Information_Component)_of_Vemurafenib_in_Vigibas> rdf:type owl:NamedIndividual ,
                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :CardiacFailure ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "10/9/2016" ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.22 ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 61 ;
                                                                                                                                  rdfs:label "IC (Information Component) of Vemurafenib in Vigibas" ,
                                                                                                                                             "IC (Information Component) of Vemurafenib in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ReportsHavingmetastatic/malignantMelanomaAsIndication
<http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#ReportsHavingmetastatic/malignantMelanomaAsIndication> rdf:type owl:NamedIndividual ,
                                                                                                                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :metastaticMalignantMelanoma ;
                                                                                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                                                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Vemurafenib ;
                                                                                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 47 ;
                                                                                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                   rdfs:label "Reports having metastatic/malignant melanoma as indication" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_fatigue/_malaise
<http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_fatigue/_malaise> rdf:type owl:NamedIndividual ,
                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Fatigue ;
                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                           rdfs:label "Reports with fatigue/ malaise" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_myocarditis/_pericarditis/_cardiomyopathy
<http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#Reports_with_myocarditis/_pericarditis/_cardiomyopathy> rdf:type owl:NamedIndividual ,
                                                                                                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsInVigibase ;
                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :cardiomyopathy ,
                                                                                                                                                                                                             :myocarditis ,
                                                                                                                                                                                                             :pericarditis ;
                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                    rdfs:label "Reports with myocarditis/ pericarditis/ cardiomyopathy" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#codeine/paracetamol
<http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#codeine/paracetamol> rdf:type owl:NamedIndividual ,
                                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02AJ06" ;
                                                                                                 rdfs:label "codeine/paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#naloxone/tilidine
<http://purl.org/OpenPVSignal/Signals/2018_3_vemurafenib_cardiacFailure.owl#naloxone/tilidine> rdf:type owl:NamedIndividual ,
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "V03AB15" ;
                                                                                               rdfs:label "naloxone / tilidine" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
